Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

Detalles Bibliográficos
Autores principales: Barrière, J., Chamorey, E., Adjtoutah, Z., Castelnau, O., Mahamat, A., Marco, S., Petit, E., Leysalle, A., Raimondi, V., Carles, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080507/
https://www.ncbi.nlm.nih.gov/pubmed/33932508
http://dx.doi.org/10.1016/j.annonc.2021.04.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080507/
https://www.ncbi.nlm.nih.gov/pubmed/33932508
http://dx.doi.org/10.1016/j.annonc.2021.04.019

Ejemplares similares